Swedish Orphan Biovitrum
245 articles about Swedish Orphan Biovitrum
-
Biogen Idec And Swedish Orphan Biovitrum Announce European Medicines Agency Validates ELOCTAァ (rFVIIIFc) Marketing Authorization Application For Review
11/3/2014
-
Swedish Orphan Biovitrum Publishes Report For The Third Quarter 2014
10/30/2014
-
Pharming Group And Swedish Orphan Biovitrum Amend And Extend Ruconest Distribution Agreement
10/13/2014
-
Swedish Orphan Biovitrum Opens North American Operations
9/22/2014
-
Swedish Orphan Biovitrum Expands Haemophilia Development Portfolio - Elects To Include Potentially Longer-Acting Haemophilia A Candidate In Collaboration Agreement With Biogen Idec, Inc. (Massachusetts)
9/19/2014
-
Swedish Orphan Biovitrum's Board Of Directors Exercises Authorization For Repurchase Of Shares For The Purpose Of Securing The Company's Commitments Under The Incentive Program
7/18/2014
-
Swedish Orphan Biovitrum Publishes Report For The Second Quarter 2014
7/18/2014
-
Invitation - Presentation Of Swedish Orphan Biovitrum's Second Quarter Results 2014
7/9/2014
-
BioSpecifics Technologies Corporation Announces Filing By Swedish Orphan Biovitrum For EU Approval Of XIAPEX For Peyronies Disease
6/26/2014
-
Swedish Orphan Biovitrum To Review Preclinical Data To Potentially Add Future Haemophilia A Candidate To Collaboration Agreement With Biogen Idec, Inc. (Massachusetts)
6/16/2014
-
Swedish Orphan BiovitrumAppoints Kirsti Gjellan As Senior Vice President Manufacturing Operations
5/27/2014
-
Biogen Idec, Inc. (Massachusetts) And Swedish Orphan Biovitrum To Donate 1 Billion International Units Of Clotting Factor To Support Treatment Of Hemophilia In Developing World
5/12/2014
-
Resolutions From Swedish Orphan Biovitrumi's AGM
5/9/2014
-
Annette Clancy Joins Swedish Orphan Biovitrum's Board Of Directors
5/9/2014
-
Swedish Orphan Biovitrum Publishes Report For The First Quarter 2014
5/8/2014
-
Swedish Orphan Biovitrum Publishes Annual Report 2013
4/16/2014
-
Swedish Orphan Biovitrum Becomes Market Authorisation Holder For Xiapex In Europe
4/7/2014
-
TiGenix : Licenses Exclusive Marketing And Distribution Rights For Chondrocelect To Swedish Orphan Biovitrum
4/3/2014
-
Notice Of Annual General Meeting In Swedish Orphan Biovitrum
4/3/2014
-
Swedish Orphan Biovitrum Assumes Direct Responsibility For Orfadin® (Nitisinone) In U.S. And Canada And Introduces Orfadin4U™
4/1/2014